Expected Early Data Report from VS-7375-101 Trial in 1H 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy VSTM?
Expected Key Milestones: Report early data from the VS-7375-101 trial in 1H 2026. Select the RP2D with cetuximab and initiate the CRC combination expansion cohort in 1H 2026. Complete enrollment in combination dose-escalation cohorts in mid-2026. Complete enrollment in monotherapy expansion cohorts in 2H 2026. Select the RP2D and plan to initiate the PDAC and NSCLC combination expansion cohorts in 2H 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VSTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VSTM
Wall Street analysts forecast VSTM stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.390
Low
14.00
Averages
15.60
High
20.00
Current: 6.390
Low
14.00
Averages
15.60
High
20.00
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Verastem Reports Q4 Earnings Beat, Stock Rises
- Earnings Highlights: Verastem reported a Q4 adjusted loss of $0.48 per share, slightly above analysts' expectations of a $0.50 loss, while revenue of $17.5 million exceeded the consensus estimate of $16.84 million, indicating strong market performance post-drug launch.
- Sales Growth: The Avmapki Fakzynja co-pack generated $17.5 million in Q4 revenue, with projections of $30.9 million for 2025, marking the company's first commercial success in the KRAS-mutated recurrent ovarian cancer market, enhancing its competitive position.
- Clinical Trial Progress: The VS-7375 cancer drug cleared multiple dose levels in early trials without safety issues, with plans to pursue Phase 2 registration-directed studies across several cancer indications, showcasing its potential in oncology treatment.
- Positive Investor Sentiment: Despite a 25% decline in VSTM stock year-to-date, shares rose nearly 3% in after-hours trading, reflecting investor optimism regarding the new therapy's early traction and upcoming clinical milestones.
See More
Verastem Q4 2025 Earnings Call Highlights
- Financial Performance: Verastem reported $17.5 million in net product revenue for Q4 2025 and $30.9 million for the full year, indicating strong market acceptance and early commercial success, with expectations for the LGSOC franchise to become self-sustaining in H2 2026.
- Clinical Progress: The company made advancements in the RAMP 205 trial, achieving a 57% overall response rate in KRAS mutant patients, suggesting that VS-7375 has significant potential in treating KRAS G12D-driven cancers, thereby reinforcing its strategic position in oncology.
- Market Adoption: By February, nearly 300 prescribers had adopted CO-PACK, with over 75% of target institutions implementing the therapy, demonstrating effective outreach to healthcare providers and robust patient support strategies.
- Future Outlook: Management reiterated a focus on maximizing CO-PACK adoption and plans to share updates on the RAMP 205 expansion cohort in Q2 2026, further driving clinical data generation and market penetration.
See More
Verastem Q4 Earnings Beat Expectations
- Earnings Highlights: Verastem reported a Q4 GAAP EPS of -$0.50, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in a loss position.
- Revenue Growth: The company achieved Q4 revenue of $17.54 million, exceeding market expectations by $0.7 million, suggesting an increase in product acceptance in the market, which could lay the groundwork for future growth.
- Clinical Developments: Verastem plans clinical updates in 2026, and despite setbacks with RAMP-203 targeting KRAS G12C NSCLC, the commitment to ongoing R&D may influence investor confidence positively.
- Rating Adjustment: Following the RAMP-203 setback, Verastem's rating has been downgraded to “Buy,” which may impact short-term stock performance but could also present an entry opportunity for long-term investors.
See More
Verastem to Announce Q4 Earnings on March 4
- Earnings Announcement: Verastem is set to release its Q4 2023 earnings on March 4 after market close, with a consensus EPS estimate of -$0.50, reflecting a 16.7% year-over-year improvement, indicating potential financial performance recovery.
- Revenue Expectations: Analysts project Verastem's Q4 revenue to reach $16.84 million, suggesting a degree of stability and growth potential in the market despite ongoing challenges.
- Historical Performance Review: Over the past two years, Verastem has beaten EPS estimates 63% of the time and revenue estimates 25% of the time, indicating a relatively reliable performance in financial forecasting that may influence investor confidence.
- Clinical Trial Updates: Following setbacks with the RAMP-203 project, Verastem has downgraded its rating to Buy and plans to provide clinical updates in 2026, demonstrating the company's proactive approach to seeking future growth opportunities despite current challenges.
See More
Verastem Oncology to Host Q4 2025 Financial Results Call
- Conference Call Announcement: Verastem Oncology will host a conference call on March 4, 2026, at 4:30 PM ET to discuss its Q4 and full-year 2025 financial results, aiming to provide investors with insights into its latest business developments and financial performance.
- Access Instructions: Investors can dial (888) 596-4144 for U.S. access or (646) 968-2525 for international calls, entering passcode 7321921 at least 10 minutes prior to the start time to ensure smooth participation in this important financial update.
- Live Webcast and Replay: The call will be available via a live audio webcast on the company's investor website, accompanied by slides, and a replay will be archived post-event, allowing investors who cannot attend live to access the information.
- Company Overview: Verastem Oncology focuses on developing new medicines for RAS/MAPK pathway-driven cancers, with products like AVMAPKI™ and FAKZYNJA™ CO-PACK already in the market, showcasing the company's innovative capabilities in the biopharmaceutical sector.
See More
Verastem Oncology Schedules Q4 2025 Financial Results Call
- Conference Call Announcement: Verastem Oncology will host a conference call on March 4, 2026, at 4:30 PM ET to discuss its Q4 and full-year 2025 financial results, reflecting the company's commitment to transparency and investor communication.
- Access Details: Investors can dial (888) 596-4144 for U.S. access or (646) 968-2525 for international calls, entering passcode 7321921 at least 10 minutes prior to the event, ensuring smooth participation.
- Live Webcast and Replay: The call will be available via a live audio webcast on the company's website under the
See More
Verastem Reports Q4 Earnings Beat, Stock Rises
- Earnings Highlights: Verastem reported a Q4 adjusted loss of $0.48 per share, slightly above analysts' expectations of a $0.50 loss, while revenue of $17.5 million exceeded the consensus estimate of $16.84 million, indicating strong market performance post-drug launch.
- Sales Growth: The Avmapki Fakzynja co-pack generated $17.5 million in Q4 revenue, with projections of $30.9 million for 2025, marking the company's first commercial success in the KRAS-mutated recurrent ovarian cancer market, enhancing its competitive position.
- Clinical Trial Progress: The VS-7375 cancer drug cleared multiple dose levels in early trials without safety issues, with plans to pursue Phase 2 registration-directed studies across several cancer indications, showcasing its potential in oncology treatment.
- Positive Investor Sentiment: Despite a 25% decline in VSTM stock year-to-date, shares rose nearly 3% in after-hours trading, reflecting investor optimism regarding the new therapy's early traction and upcoming clinical milestones.
See More
Verastem Q4 2025 Earnings Call Highlights
- Financial Performance: Verastem reported $17.5 million in net product revenue for Q4 2025 and $30.9 million for the full year, indicating strong market acceptance and early commercial success, with expectations for the LGSOC franchise to become self-sustaining in H2 2026.
- Clinical Progress: The company made advancements in the RAMP 205 trial, achieving a 57% overall response rate in KRAS mutant patients, suggesting that VS-7375 has significant potential in treating KRAS G12D-driven cancers, thereby reinforcing its strategic position in oncology.
- Market Adoption: By February, nearly 300 prescribers had adopted CO-PACK, with over 75% of target institutions implementing the therapy, demonstrating effective outreach to healthcare providers and robust patient support strategies.
- Future Outlook: Management reiterated a focus on maximizing CO-PACK adoption and plans to share updates on the RAMP 205 expansion cohort in Q2 2026, further driving clinical data generation and market penetration.
See More
Verastem Q4 Earnings Beat Expectations
- Earnings Highlights: Verastem reported a Q4 GAAP EPS of -$0.50, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in a loss position.
- Revenue Growth: The company achieved Q4 revenue of $17.54 million, exceeding market expectations by $0.7 million, suggesting an increase in product acceptance in the market, which could lay the groundwork for future growth.
- Clinical Developments: Verastem plans clinical updates in 2026, and despite setbacks with RAMP-203 targeting KRAS G12C NSCLC, the commitment to ongoing R&D may influence investor confidence positively.
- Rating Adjustment: Following the RAMP-203 setback, Verastem's rating has been downgraded to “Buy,” which may impact short-term stock performance but could also present an entry opportunity for long-term investors.
See More
Verastem to Announce Q4 Earnings on March 4
- Earnings Announcement: Verastem is set to release its Q4 2023 earnings on March 4 after market close, with a consensus EPS estimate of -$0.50, reflecting a 16.7% year-over-year improvement, indicating potential financial performance recovery.
- Revenue Expectations: Analysts project Verastem's Q4 revenue to reach $16.84 million, suggesting a degree of stability and growth potential in the market despite ongoing challenges.
- Historical Performance Review: Over the past two years, Verastem has beaten EPS estimates 63% of the time and revenue estimates 25% of the time, indicating a relatively reliable performance in financial forecasting that may influence investor confidence.
- Clinical Trial Updates: Following setbacks with the RAMP-203 project, Verastem has downgraded its rating to Buy and plans to provide clinical updates in 2026, demonstrating the company's proactive approach to seeking future growth opportunities despite current challenges.
See More
Verastem Oncology to Host Q4 2025 Financial Results Call
- Conference Call Announcement: Verastem Oncology will host a conference call on March 4, 2026, at 4:30 PM ET to discuss its Q4 and full-year 2025 financial results, aiming to provide investors with insights into its latest business developments and financial performance.
- Access Instructions: Investors can dial (888) 596-4144 for U.S. access or (646) 968-2525 for international calls, entering passcode 7321921 at least 10 minutes prior to the start time to ensure smooth participation in this important financial update.
- Live Webcast and Replay: The call will be available via a live audio webcast on the company's investor website, accompanied by slides, and a replay will be archived post-event, allowing investors who cannot attend live to access the information.
- Company Overview: Verastem Oncology focuses on developing new medicines for RAS/MAPK pathway-driven cancers, with products like AVMAPKI™ and FAKZYNJA™ CO-PACK already in the market, showcasing the company's innovative capabilities in the biopharmaceutical sector.
See More
Verastem Oncology Schedules Q4 2025 Financial Results Call
- Conference Call Announcement: Verastem Oncology will host a conference call on March 4, 2026, at 4:30 PM ET to discuss its Q4 and full-year 2025 financial results, reflecting the company's commitment to transparency and investor communication.
- Access Details: Investors can dial (888) 596-4144 for U.S. access or (646) 968-2525 for international calls, entering passcode 7321921 at least 10 minutes prior to the event, ensuring smooth participation.
- Live Webcast and Replay: The call will be available via a live audio webcast on the company's website under the
See More
